Clinical Trial Update: Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial update on PEG-rIL-29 plus ribavirin for chronic hepatitis C infection, focusing on efficacy and safety. The current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG-rIL-29 (pegylated interleukin-29)
• Ribavirin (ribavirin)

Snippet

Sponsor: ZymoGenetics | Conditions: Hepatitis C, Chronic | Phase 2 | Status: UNKNOWN